|
Assessment of Human Antihuman Antibodies to Eculizumab After Long-Term Treatment in Patients With Paroxysmal Nocturnal Hemoglobinuria
|
Dec 2015
|
Am J Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Impact of comorbidities by ACE-27 in the Revised-IPSS for patients with myelodysplastic syndromes
|
Jan 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience
|
Aug 2017
|
Am J Hematol
|
aplastic anemia
|
|
Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: A treatment versus no-treatment study
|
Dec 2015
|
Am J Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Calculator-free point-of-care prognostication in myelodysplastic syndromes.
|
Jan 2019
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Pediatric aplastic anemia and refractory cytopenia: A retrospective analysis assessing outcomes and histomorphologic predictors
|
Jan 2015
|
Am J Hematol
|
aplastic anemia
|
|
Laboratory tests for paroxysmal nocturnal hemoglobinuria (PNH).
|
Oct 2013
|
Am J Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution
|
Apr 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes
|
Aug 2012
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R
|
Sep 2017
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
